Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.68 (market cap $39.89B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.28. Which is the better fit depends on your goals.
| ALNY | YINN | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $56.62 |
52-Week Low | $278.09 | $21.45 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
YINN trades at $25.36, up 0.6% with a bullish technical signal despite mixed indicators. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $26. Recent news highlights China's AI investment push and improved macro sentiment, though geopolitical tensions with the U.S. persist. The fund's leveraged structure amplifies both gains and risks in Chinese equities.
Outlook remains cautious due to YINN's 3x leverage amplifying volatility. Opportunities exist from China's $295 billion AI infrastructure plan and strong export growth, but risks include U.S.-China tech rivalry, regulatory scrutiny, and value trap concerns. Investors should weigh leveraged exposure against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
